EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study

Erkut H Borazanci iD, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio, Elena Gabriela Chiorean, Roland T Skeel, Olatunji B Alese iD, Dana B Cardin, Christos Fountzilas iD, Wahid T Hanna, Alexis D Leal und 7 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae210 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Oncologist, 2024. Verfasst von Erkut H Borazanci und 18 weiteren Autor:innen. Beteiligte Einrichtung: HonorHealth Research Institute, Scottsdale, AZ, United States. Hauptthemen laut MEDLINE: Albumins, Carcinoma, Pancreatic Ductal, Paclitaxel, Pancreatic Neoplasms. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Corcept Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Modulation of glucocorticoid receptor (GR) activity in tumor cells enhances chemotherapy efficacy. We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines. Patients and Methods In this open-label, single-arm, phase III study, patients received once-daily oral relacorilant (100 mg, titrated to 150 mg in 25 mg increments/cycle) and nab-paclitaxel (80 mg/m2) on days 1, 8, and 15 of 28-day cycles. The primary efficacy endpoint was objective response rate (ORR) by blinded independent central review. Progression-free survival (PFS), overall survival (OS), target gene modulation, and safety were also assessed.

Results

Of 43 patients enrolled, 31 were evaluable for ORR (12 did not reach first postbaseline radiographic assessment). An interim analysis to assess whether ORR was ≥10% showed no confirmed responses and the study was discontinued. Two (6.5%) patients attained unconfirmed partial responses and 15 (48.4%) had stable disease. Fourteen of 31 (45.2%) patients had reductions in target lesion size, despite prior nab-paclitaxel exposure in 12 of the 14. Median PFS and OS were 2.4 months (95% CI, 1.4-4.2) and 3.9 months (95% CI, 2.8-4.9), respectively. The most common adverse events were fatigue and nausea. RNA analysis confirmed that relacorilant plus nab-paclitaxel suppressed 8 cortisol target genes of interest.

Conclusion

Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminsCarcinoma, Pancreatic DuctalPaclitaxelPancreatic NeoplasmsIsoquinolinesPyrazolesPyridinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasis

Stichwörter der Autor:innen

PDACmetastatic pancreatic cancernab-paclitaxelrelacorilant

Substanzen

130-nm albumin-bound paclitaxelAlbuminsPaclitaxelrelacorilantIsoquinolinesPyrazolesPyridines

Autor:innen und Institutionen

  • HonorHealth Research Institute, Scottsdale, AZ, United States.
  • Allegheny Health Network Cancer Institute, Pittsburgh, PA, United States.
  • City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
  • Nebraska Cancer Specialists, Omaha, NE, United States.
  • Goshen Center for Cancer Care, Goshen, IN, United States.
  • University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, United States.

ORCID-Profile: Erkut H Borazanci, Olatunji B Alese, Christos Fountzilas

Förderung

  • NCI NIH HHS
  • Corcept Therapeutics

Zitieren

APA

Borazanci, E. H., Bahary, N., Chung, V., Huyck, T. K., Kio, E. A., Chiorean, E. G., Skeel, R. T., Alese, O. B., Cardin, D. B., Fountzilas, C., Hanna, W. T., Leal, A. D., Lee, V., Noonan, A. M., Philip, P. A., Wainberg, Z. A., Pashova, H., Mann, G., & Oberstein, P. E. (2024). Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. The Oncologist. https://doi.org/10.1093/oncolo/oyae210

Vancouver

Borazanci EH, Bahary N, Chung V, Huyck TK, Kio EA, Chiorean EG, et al. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. The Oncologist. 2024. doi:10.1093/oncolo/oyae210

BibTeX
@article{Borazanci2024,
  author = {Borazanci, Erkut H and Bahary, Nathan and Chung, Vincent and Huyck, Timothy K and Kio, Ebenezer A and Chiorean, Elena Gabriela and Skeel, Roland T and Alese, Olatunji B and Cardin, Dana B and Fountzilas, Christos and Hanna, Wahid T and Leal, Alexis D and Lee, Valerie and Noonan, Anne M and Philip, Philip A and Wainberg, Zev A and Pashova, Hristina and Mann, Grace and Oberstein, Paul E},
  title = {Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae210}
}
Kostenlos starten →